On March 18, the U.S. clinical trials registry website showed that Kite Pharma, a subsidiary of Gilead Sciences (GILD.US), has launched the first Phase III clinical trial for KITE-753. KITE-753 is a bicistronic autologous CAR-T cell therapy targeting both CD19 and CD20. The study is a randomized, multicenter, open-label clinical trial (n=550) designed to evaluate the efficacy and safety of KITE-753 compared to axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma (LBCL) who have previously received one line of therapy. The primary endpoints of the study are the proportion of patients achieving complete response (CR) at six months and event-free survival (EFS) within 36 months. Results from the dose 3 cohort showed that among 14 patients who had not previously received CAR-T cell therapy, 11 achieved CR, representing a CR rate of 79%. In the overall population, among 20 CAR-T therapy-naive patients, 14 achieved CR, yielding a CR rate of 70%.